Landcent’s research comprises of not just basic research and development on field and in the laboratory, but also has strategic and applied research intended at controlling and eradicating malaria worldwide. Our efforts are coordinated with the China Academy of Sciences, an institution in China, functioning as the national scientific think tank and academic governing body, providing advisory and appraisal services on issues stemming from social development, science and technology progress. It is the world’s largest research organization, comprising over 60,000 researchers working in 114 institutes and has been consistently ranked among the top research organizations around the world. The company’s long-term plans are centered on the development of technologies for the prevention of Tuberculosis (TB) & HIV/AIDS.
For more on China Academy of Sciences Click here
For more on Shanghai Institute of Organic Chemistry Click here
Our R&D team serves as the backbone for new product innovations and constant development to put an end to Malaria. Our lab holds the latest equipment and we possess more than 8 patents in the industry. 2 invention patents and 6 utility patents from ‘The State Intellectual Property Office of China.’
Our researchers’ are putting their best foot forward to witness a major breakthrough in fighting Malaria.
Landcent established by Huali (Danny) Lin and Arun Prabhu with a vision to be a game-changer in the field of Malaria and to be rooted as a powerhouse of disease prevention by creating effective tools.
Malaria prevention and eradication discussions commenced with the WHO, as part of an extensive Malaria approach.
Engaged in Screening and Evaluation of Compounds in partnership with Shanghai Institute of Organic Chemistry, China Academy of Sciences.
Achieved MVP, first patent application and collaboration with Donghua University.
Acquired China National Hi-Tech Enterprise Certificate and collaborated with the Shanghai Institute of Organic Chemistry, responsible for the discovery of Artemisinin.
Obtained Pre-A investment from China CSC Group and initiated the ‘Landcent Engineering and Technology Center’. A joint Lab with the Shanghai Institute of Organic Chemistry was also set up.
Accredited with WHO GCDPP membership. Officially ventured into the pharmaceutical arena and initiated the development of anti-malarial pills and repellent range.
Started Field Trials and Toxicology Reviews for products in the WHO approval process; Conducted comprehensive clinical investigation on the Anti-Malarial pill. Landcent Europe B.V. incorporated.
Product validated in real-time field setting for the first time with residual effect of 17 -22 months, twice as much as any other product in the market.
Secured the Bill & Melinda Gates Foundation grant for an innovative project on the discovery of active ingredient from entirely natural compounds.
Recognized as a Global Finalist (Winner) of the Accelerate2030. A program founded by UNDP and Impact Hub Geneva.
Preparation of data from Vector Control Phase I, II & III trials with collaborating laboratories in East Africa, West Africa & Asia.
Submission of data package to the WHO for items in WHO development pipeline.
Receive WHO Pre-Qualification for Bednets – NeoNet 2.0™, Anti-Malarial Pill – Codispaq™ & IRS – Durus™.
Target sales growth and plan for scaling up of market share to at least 15 countries by 4Q 2025.
Target sales growth and plan for scaling up of market share to at least 30 countries by 4Q 2026
You can adjust all of your cookie settings by navigating the tabs on the left hand side.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.